Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 46, 2009, Pages 19611-19616

  Moench, Ian ^a,b   Prentice, Howard ^a,b   Rickaway, Zach ^a   Weissbach, Herbert ^b  

^a College of Biomedical Science ^*  (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cardioprotection; Myocardial ischemia

Indexed keywords

CHELERYTHRINE; HEAT SHOCK PROTEIN 27; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SULINDAC; SULINDAC SULFONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPOXIA; ISOLATED HEART; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REOXYGENATION; SIGNAL TRANSDUCTION; ANIMAL; CELL PROTECTION; DISEASE MODEL; DRUG EFFECT; HEART; HEART INFARCTION PREVENTION; HEART MUSCLE; METABOLISM;

ANIMALIA; RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; HEART; HSP27 HEAT-SHOCK PROTEINS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE C; RATS; REACTIVE OXYGEN SPECIES; SULINDAC;

EID: 73349104666     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0911046106     Document Type: Article

References (49)

1. Vane J (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
2. Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529-1536.
3. Guldenschuh I, et al. (2001) Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum 44:1090-1097.
4. Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H (2009) Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol 8:29-32.
5. Marchetti M, Resnick L, Gamliel E, Weissbach H, Binninger D (2009) Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One 4(6):e5804.
6. Etienne F, Resnick L, Sagher D, Brot N, Weissbach H (2003) Reduction of Sulindac to its active metabolite, sulindac sulfide: Assay and role of the methionine sulfoxide reductase system. Biochem Biophys Res Commun 312:1005-1010.
7. Weissbach H, Resnick L, Brot N (2005) Methionine sulfoxide reductases: History and cellular role in protecting against oxidative damage. Biochim Biophys Acta 1703:203-212.
8. Moskovitz J, et al. (2001) Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci USA 98:12920-12925.
9. Ruan H, et al. (2002) High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc Natl Acad Sci USA 99:2748-2753.
10. Bolli R (2000) The late phase of preconditioning. Circ Res 87:972-983.
11. Dawn B, et al. (2004) Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37:51-61.
12. Yeh CH, Wang YC, Wu YC, Lin YM, Lin PJ (2004) Ischemic preconditioning or heat shock pretreatment ameliorates neuronal apoptosis following hypothermic circulatory arrest. J Thorac Cardiovasc Surg 128:203-210.
13. Gross GJ (2003) Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 35:709-718.
14. Budas GR, Mochly-Rosen D (2007) Mitochondrial protein kinase C ε (PKCε): Emerging role in cardiac protection from ischaemic damage. Biochem Soc Trans 35:1052-1054.
15. Raval. AP, Dave KR, Mochly-Rosen D, Sick TJ, Pérez-Pinzón MA (2003) Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. J Neurosci 23:384-391.
16. Hausenloy DJ, Yellon DM (2006) Survival kinases in preconditioning and postconditioning. Cardiovasc Res 70:240-253.
17. Gross ER, Hsu AK, Gross GJ (2004) Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: Role of 12-Lipoxygenase. JPET 310:185-191.
18. Jones SP, Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:16-23.
19. Xuan YT, et al. (2000) Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am J Physiol Heart Circ Physiol 279:H2360-H2371.
20. Dawson VL, Dawson TM (2000) Neuronal ischaemic preconditioning. Trends Pharmacol Sci 21:423-424.
21. Li RC, et al. (2000) PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol 279:H1679-H1689.
22. Guo Y, et al. (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96:11507-11512.
23. West MB, et al. (2008) Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 118:1970-1978.
24. Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC (2000) Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: Evidence from gene-knockout mice. Circulation 102:902-907.
25. Efthymiou CA, et al. (2004) Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol 99:392-394.
26. Sanada S, et al. (2001) Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 88:175-180.
27. Venkatakrishnan CD, et al. (2006) Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am J Physiol Heart Circ Physiol 291:H2680-H2691.
28. Dana A, Jonassen AK, Yamashita N, Yellon DM (2000) Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 101:2841-2848.
29. Marais E, et al. (2005) The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. Basic Res Cardiol 100:35-47.
30. Peart JN, Gross ER, Headrick JP, Gross GJ (2007) Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection. J Mol Cell Cardiol 42:972-980.
31. Murashov AK, et al. (2001) Crosstalk between p38, Hsp25, and Akt in spinal motor neurons after sciatic nerve injury. Brain Res Mol Brain Res 93:199-208.
32. Sun JZ, et al. (1996) Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest 97:562-576.
33. Stein AB, et al. (2004) Delayed adaptation of the heart to stress: Late preconditioning. Stroke 35:2676-2679.
34. Joyeux-Faure M, Arnaud C, Godin-Ribuot D, Ribuot C (2003) Heat stress preconditioning and delayed myocardial protection: What is new? Cardiovasc Res 60:469-477.
35. Li H, Wallerath T, Münzel T, Förstermann U (2002) Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7:149-164.
36. Akita Y, et al. (2007) Exercise-induced activation of cardiac sympathetic nerve triggers cardioprotection via redox-sensitive activation of eNOS and upregulation of iNOS. Am J Physiol Heart Circ Physiol 292:H2051-H2059.
37. Kukreja RC (2001) Essential role of oxygen radicals in delayed pharmacological preconditioning. J Mol Cell Cardiol 33:1395-1398.
38. Vondriska TM, et al. (2001) Protein kinase C epsilon-Src modules direct signal transduction in nitric oxide-induced cardioprotection: Complex formation as a means for cardioprotective signaling. Circ Res 88:1306-1313.
39. Ciolino HP, MacDonald CJ, Memon OS, Bass SE, Yeh GC (2006) Sulindac regulates the aryl hydrocarbon receptor-mediated expression of phase 1 metaoblic enzymes in vivo and in vitro. Carcinogenesis 27:1586-1592.
40. Ciolino HP, Bass SE, MacDonald CJ, Cheng RY, Yeh GC (2008) Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer 122:990-998.
41. Hattori R, Otani H, Maulik N, Das DK (2002) Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am J Physiol Heart Circ Physiol 282:H1988-H1995.
42. Athar M, et al. (2004) Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice. Toxicol Appl Pharmacol 195:370-378.
43. Mesches MH, et al. (2004) Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiol Aging 25:315-324.
44. Dairam A, Müller AC, Daya S (2007) Nonsteroidal anti-inflammatory agents, tolmetin, and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats. Life Sci 80:1431-1438.
45. Charles HH, Steven B (2008) Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther 13:41-50.
46. Webster KA, et al. (1999) Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 104:239-252.
47. Skrzypiec-Spring M, Grotthus B, Szelag A, Schulz R (2007) Isolated heart perfusion according to Langendorff- Still viable in the new millennium. J Pharmacol Toxicol Methods 55:113-126.
48. Yoshida T, Maulik N, Engelman RM, Ho-YS, Das DK (2000) Targeted disruption of the mouse SODI gene makes the heart vulnerable to ischemic reperfusion injury. Circ Res 86:264-269.
49. Shinmura K, et al. (2002) Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 91:240-246.